Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Merck KGaA. (6/17/14). "Press Release: Merck Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod (ONO-4641)". Darmstadt.

Organisations Organisation Merck Serono (division of Merck KGaA)
  Group Merck (DE) (Group)
  Organisation 2 Ono Pharmaceutical Co., Ltd. (TSE: 4528)
  Group Ono Pharmaceutical (Group)
Products Product MS DRUGS
  Product 2 clinical research
Index term Index term Merck (DE)–Ono Pharmaceutical: ceralifimod, 201110–201406 license ww excl except JP + KR + Taiwan TERMINATED 6/14
     


Merck announced today that it has reached a mutual agreement with Ono Pharmaceutical Co., Ltd., Osaka, Japan, to terminate the license agreement on ceralifimod (ONO-4641) because it does not meet Merck's threshold for continued investment. Merck obtained worldwide exclusive license rights from Ono Pharmaceutical for the development and commercialization of ceralifimod (ONO-4641) in multiple sclerosis (MS) outside of Japan, Korea and Taiwan in October 2011. The drug candidate is currently in clinical development (Phase II).

Merck Serono, the biopharmaceutical division of Merck, remains committed to improving the lives of people with MS, and will continue to pursue external collaborations and internal development programs aimed at identifying and developing high quality candidate molecules with the goal of making a real difference in the lives of people with MS.


About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million patients have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.


All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website www.merckgroup.com/media. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.


Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

Your Contact
Dr. Gangolf Schrimpf
+49(0)6151 72 9591

   
Record changed: 2017-04-02

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top